$495 Million is the total value of Avoro Capital Advisors LLC's 44 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 39.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $42,870,000 | +70.1% | 1,486,460 | +87.6% | 8.66% | +95.8% |
| IMMU | Buy | IMMUNOMEDICS INC | $33,996,000 | +42.4% | 9,263,340 | +26.1% | 6.87% | +64.0% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $33,136,000 | -14.7% | 400,000 | -4.7% | 6.69% | -1.8% |
| LBIO | Buy | LION BIOTECHNOLOGIES INC | $31,418,000 | -10.3% | 4,520,643 | +6.2% | 6.35% | +3.2% |
| TSRO | Sell | TESARO INC | $31,159,000 | +11.9% | 231,700 | -16.6% | 6.30% | +28.9% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $27,713,000 | -67.1% | 1,010,300 | -26.3% | 5.60% | -62.1% |
| Buy | NEURODERM LTD | $23,450,000 | +84.8% | 1,056,303 | +53.9% | 4.74% | +112.7% | |
| DERM | Sell | DERMIRA INC | $23,224,000 | -14.8% | 765,709 | -5.0% | 4.69% | -1.9% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $23,089,000 | +22.4% | 610,000 | +22.0% | 4.66% | +40.9% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $20,937,000 | -15.7% | 541,000 | +10.3% | 4.23% | -3.0% |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $20,800,000 | – | 170,000 | +100.0% | 4.20% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $19,967,000 | -26.9% | 4,017,577 | +8.9% | 4.03% | -15.8% |
| BMY | Sell | BRISTOL MYERS SQUIBB CO. | $16,655,000 | -22.8% | 285,000 | -28.7% | 3.36% | -11.0% |
| SGEN | Buy | SEATTLE GENETICS INC | $15,595,000 | +104.1% | 295,533 | +108.9% | 3.15% | +134.9% |
| AGEN | Buy | AGENUS INC | $15,452,000 | -42.1% | 3,750,430 | +0.9% | 3.12% | -33.3% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $14,390,000 | -28.2% | 995,838 | +14.6% | 2.91% | -17.3% |
| ASND | Buy | ASCENDIS PHARMAsponsored adr | $11,035,000 | +1114.0% | 545,203 | +1106.1% | 2.23% | +1301.9% |
| TLGT | Buy | TELIGENT INC | $10,997,000 | -11.6% | 1,663,619 | +1.6% | 2.22% | +1.7% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $10,327,000 | +69.8% | 1,631,502 | +18.3% | 2.09% | +95.5% |
| AKBA | Sell | AKEBIA THERAPEUTICS INC | $8,656,000 | +1.3% | 831,515 | -12.0% | 1.75% | +16.6% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $7,164,000 | -27.2% | 1,508,201 | +1.3% | 1.45% | -16.2% |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $7,135,000 | -39.8% | 1,456,056 | -4.9% | 1.44% | -30.7% |
| VCYT | Sell | VERACYTE INC | $7,020,000 | +0.4% | 906,999 | -1.3% | 1.42% | +15.6% |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $6,084,000 | -55.8% | 381,466 | -53.9% | 1.23% | -49.2% |
| ALIM | Buy | ALIMERA SCIENCES INC | $4,357,000 | -18.2% | 4,034,488 | +12.9% | 0.88% | -5.9% |
| CASC | New | CASCADIAN THERAPEUTICS INC | $3,971,000 | – | 921,248 | +100.0% | 0.80% | – |
| XNCR | New | XENCOR INC | $3,290,000 | – | 125,000 | +100.0% | 0.66% | – |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $3,284,000 | +69.9% | 270,289 | +0.8% | 0.66% | +95.6% |
| FBIO | Sell | FORTRESS BIOTECH INC | $3,241,000 | -19.6% | 1,200,342 | -11.5% | 0.66% | -7.4% |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $3,098,000 | -29.8% | 216,619 | -19.3% | 0.63% | -19.2% |
| ONS | Buy | ONCOBIOLOGICS INC | $2,057,000 | +7.4% | 683,531 | +51.6% | 0.42% | +23.8% |
| CLLS | Buy | CELLECTIS - ADRsponsored adr | $1,646,000 | +16.5% | 97,096 | +65.5% | 0.33% | +34.3% |
| Sell | PERNIX THERAPEUTICS HOLDINGS INCconvertible debt | $1,479,000 | -27.9% | 6,000,000 | -14.3% | 0.30% | -16.9% | |
| ARRY | New | ARRAY BIOPHARMA INC | $1,406,000 | – | 160,000 | +100.0% | 0.28% | – |
| Sell | TRILLIUM THERAPEUTICS INC | $1,285,000 | -72.5% | 227,399 | -28.0% | 0.26% | -68.3% | |
| CPRX | New | CATALYST PHARMACEUTICALS INC | $1,198,000 | – | 1,141,149 | +100.0% | 0.24% | – |
| BDSI | New | BIODELIVERY SCIENCES INTL INC | $1,127,000 | – | 644,176 | +100.0% | 0.23% | – |
| SRPT | Buy | SAREPTA THERAPEUTICS INCput | $615,000 | +30650.0% | 150,000 | +98.4% | 0.12% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INCcall | $413,000 | – | 200,000 | +100.0% | 0.08% | – |
| ONSIZ | ONCOBIOLOGICS INC - WARRANT Bwarrant | $184,000 | -21.0% | 233,333 | 0.0% | 0.04% | -9.8% | |
| ONSIW | ONCOBIOLOGICS INC - WARRANT Awarrant | $44,000 | -60.7% | 233,333 | 0.0% | 0.01% | -55.0% | |
| AGEN | AGENUS INCcall | $25,000 | -96.9% | 1,000,000 | 0.0% | 0.01% | -96.4% | |
| IMMU | IMMUNOMEDICS INCcall | $23,000 | -56.6% | 300,800 | 0.0% | 0.01% | -44.4% | |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -46,082 | -100.0% | -0.05% | – |
| NK | Exit | NANTKWEST INC | $0 | – | -72,412 | -100.0% | -0.10% | – |
| VCEL | Exit | VERICEL CORP | $0 | – | -215,744 | -100.0% | -0.11% | – |
| CEMP | Exit | CEMPRA INC | $0 | – | -30,000 | -100.0% | -0.13% | – |
| OMED | Exit | ONCOMED PHARMACEUTICALS INC | $0 | – | -85,000 | -100.0% | -0.17% | – |
| VSAR | Exit | VERSARTIS INC | $0 | – | -95,742 | -100.0% | -0.21% | – |
| INNL | Exit | INNOCOLL HOLDINGS PLCshares | $0 | – | -468,148 | -100.0% | -0.48% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS INC | $0 | – | -179,565 | -100.0% | -0.49% | – |
| SRPT | Exit | SAREPTA THERAPUTICS INCcall | $0 | – | -190,000 | -100.0% | -1.06% | – |
| AGIO | Exit | AGIOS PHARMACEUTICALS INC | $0 | – | -150,000 | -100.0% | -1.39% | – |
| CASC | Exit | CASCADIAN THERAPEUTICS INC | $0 | – | -5,611,323 | -100.0% | -1.62% | – |
| GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -133,600 | -100.0% | -3.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.